Skip to main content
. 2023 Jan 8;24(2):1227. doi: 10.3390/ijms24021227

Figure 2.

Figure 2

Effect of ICSs combined with montelukast on the expression of IL-25, IL-33, and TSLP. A549 cells were incubated with solvent control (Con), 1 μM montelukast alone (Mon), or an ICS (fluticasone (Flu) or budesonide (Bud)) combined with montelukast for 3 h. The supernatant for IL-25, IL-33, and TSLP protein measurement were collected after treatment for 24 h in A549 cells or 96 h in ALI cultures. The montelukast-induced changes in the mRNA expression of IL25 (A), IL33 (B), and TSLP (C) were suppressed by fluticasone (n = 5). Budesonide exerted a similar suppressive effect on IL25 (D), IL33 (E), and TSLP (F) mRNA expression when administered in combination with montelukast (n = 5). The montelukast-induced IL-25, IL-33, and TSLP protein expression were decreased by fluticasone (G) or budesonide (H) (n = 4). Fluticasone or budesonide also suppressed montelukast-induced IL-25, IL-33, and TSLP protein expression in ALI cultures (I) (n = 4). The mRNA and protein expression of IL-25, IL-33, and TSLP was detected using real-time PCR or ELISA. means ± SD. * p < 0.05, ** p < 0.01, and *** p < 0.001 compare with solvent control (Con); # p < 0.05, ## p < 0.01, and ### p < 0.001 compare with montelukast alone (Mon).